Switch theme
Sign up to access all valuation multiples
Biohit Oyj is a biotechnology company. It manufactures products that bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry. Biohit's product portfolio consists of diagnostic tests, analysis systems, products that bind carcinogenic acetaldehyde into harmless compounds and monoclonal antibodies and service laboratory operations.
1988
46
LTM Revenue $16.2M
LTM EBITDA $3.1M
$34.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Biohit has a last 12-month revenue of $16.2M and a last 12-month EBITDA of $3.1M.
In the most recent fiscal year, Biohit achieved revenue of $15.3M and an EBITDA of $3.1M.
Biohit expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Biohit valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $14.0M | $15.3M | XXX | XXX | XXX |
| Gross Profit | $7.6M | $8.9M | XXX | XXX | XXX |
| Gross Margin | 54% | 58% | XXX | XXX | XXX |
| EBITDA | $2.2M | $3.1M | XXX | XXX | XXX |
| EBITDA Margin | 15% | 20% | XXX | XXX | XXX |
| Net Profit | $0.6M | $2.0M | XXX | XXX | XXX |
| Net Margin | 5% | 13% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Biohit's stock price is EUR 3 (or $3).
Biohit has current market cap of EUR 38.3M (or $41.1M), and EV of EUR 32.1M (or $34.5M).
See Biohit trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $34.5M | $41.1M | XXX | XXX | XXX | XXX | $0.18 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Biohit has market cap of $41.1M and EV of $34.5M.
Biohit's trades at 2.1x LTM EV/Revenue multiple, and 11.2x LTM EBITDA.
Analysts estimate Biohit's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Biohit and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $34.5M | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | 11.1x | XXX | XXX | XXX |
| P/E | 14.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 174.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBiohit's NTM/LTM revenue growth is 17%
Biohit's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Biohit's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Biohit's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Biohit and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 44% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 37% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 47% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biohit acquired XXX companies to date.
Last acquisition by Biohit was XXXXXXXX, XXXXX XXXXX XXXXXX . Biohit acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Biohit founded? | Biohit was founded in 1988. |
| Where is Biohit headquartered? | Biohit is headquartered in Finland. |
| How many employees does Biohit have? | As of today, Biohit has 46 employees. |
| Is Biohit publicy listed? | Yes, Biohit is a public company listed on HEL. |
| What is the stock symbol of Biohit? | Biohit trades under BIOBV ticker. |
| When did Biohit go public? | Biohit went public in 1999. |
| Who are competitors of Biohit? | Similar companies to Biohit include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Biohit? | Biohit's current market cap is $41.1M |
| What is the current revenue of Biohit? | Biohit's last 12-month revenue is $16.2M. |
| What is the current EBITDA of Biohit? | Biohit's last 12-month EBITDA is $3.1M. |
| What is the current EV/Revenue multiple of Biohit? | Current revenue multiple of Biohit is 2.1x. |
| What is the current EV/EBITDA multiple of Biohit? | Current EBITDA multiple of Biohit is 11.2x. |
| What is the current revenue growth of Biohit? | Biohit revenue growth between 2023 and 2024 was 9%. |
| Is Biohit profitable? | Yes, Biohit is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
